(via TheNewswire)

Vancouver, British Columbia – TheNewswire - March 16, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announces that pursuant to its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”), a patent application has been filed by Clearmind with the Intellectual Property Department  in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).

This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.

The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors ( SSRIs ) and other conventional options.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. Clearmind’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND". For further information, visit: https://www.clearmindmedicine.com

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking information in this news release includes, without limitation, statements regarding: the potential therapeutic benefits of the MEAI-PEA combination therapy for treatment of major depressive disorders; the potential for the MEAI-PEA combination to offer a safer, more accessible and more affordable alternative to existing antidepressants, including SSRIs and other conventional treatments; the presumed mechanism of action of the combination therapy as a non-hallucinogenic neuroplastogen; the anticipated demand for novel treatments for major depressive disorder;  the Company's ability to advance the collaboration with Clearmind Medicine Inc. and develop the combination therapy toward commercialization; and the ability of Clearmind to obtain patent protection in respect of the patent application filed with the Intellectual Property Department in Hong Kong.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information.

These risks and uncertainties include, but are not limited to: the early stage of development of the MEAI-PEA combination and the inherent uncertainty of preclinical and clinical outcomes; the risk that the combination therapy may not demonstrate the anticipated safety, efficacy, or cost-effectiveness advantages over existing treatments for major depressive disorder; the risk that the patent application filed in Hong Kong may not result in a granted patent, or that any patent granted may not provide adequate protection for the combination therapy;; the ability of the Company and Clearmind Medicine Inc. to advance the collaboration on acceptable terms; the ability of the Company to obtain the required regulatory approvals; the ability of the Company to obtain and maintain adequate intellectual property protection for the combination therapy; compliance with applicable laws and regulations; the ability of the Company to raise additional capital to fund future operations; general business, financial market, economic, competitive, political and social uncertainties; and other risks and uncertainties described in the Company's public filings available on SEDAR+ at www.sedarplus.ca .

There can be no assurance that forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

Copyright (c) 2026 TheNewswire - All rights reserved.